286 related articles for article (PubMed ID: 9119123)
41. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
42. Safety issues of animal products used in serum-free media.
Merten OW
Dev Biol Stand; 1999; 99():167-80. PubMed ID: 10404888
[TBL] [Abstract][Full Text] [Related]
43. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses.
Wisher M
Cancer Gene Ther; 2002 Dec; 9(12):1056-61. PubMed ID: 12522444
[TBL] [Abstract][Full Text] [Related]
44. Criteria for the choice of viruses in validation studies.
Minor PD
Dev Biol Stand; 1993; 81():215-9. PubMed ID: 8174805
[TBL] [Abstract][Full Text] [Related]
45. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
46. Viral safety of C1-inhibitor NF.
Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
[TBL] [Abstract][Full Text] [Related]
47. Issues of biological assays for viral vaccines.
Lee CK
Dev Biol Stand; 1996; 88():41-7. PubMed ID: 9119161
[TBL] [Abstract][Full Text] [Related]
48. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
49. Examination of the biological safety of a drug derived from mammalian organs.
Hübner GE; Koch RC; Sprenger KB; Stadler PJ; Gölker CF
Arzneimittelforschung; 1996 Jun; 46(6):657-61. PubMed ID: 8767361
[TBL] [Abstract][Full Text] [Related]
50. Validation of biopharmaceutical purification processes for virus clearance evaluation.
Darling A
Mol Biotechnol; 2002 May; 21(1):57-83. PubMed ID: 11989660
[TBL] [Abstract][Full Text] [Related]
51. [Viral safety of biological medicinal products].
Stühler A; Blümel J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
[TBL] [Abstract][Full Text] [Related]
52. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
53. Adventitious agents from animal-derived raw materials--a method of risk assessment.
Foster LG
Dev Biol Stand; 1996; 88():283-90. PubMed ID: 9119152
[TBL] [Abstract][Full Text] [Related]
54. At what stage should virus inactivation be carried out?
Dorner F; Barrett PN; Eibl J
Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
[TBL] [Abstract][Full Text] [Related]
55. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
[TBL] [Abstract][Full Text] [Related]
56. Theoretical considerations on viral inactivation or elimination.
Willkommen H; Löwer J
Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
[No Abstract] [Full Text] [Related]
57. Minimum safety requirements for preclinical testing.
Dorner F; Barrett PN; Schwartz HP; Eibl H
Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
[TBL] [Abstract][Full Text] [Related]
58. Introduction to the issues: recently developed methods for characterizing cell lines.
Kozak RW
Dev Biol Stand; 1992; 76():21-4. PubMed ID: 1478337
[TBL] [Abstract][Full Text] [Related]
59. Regulatory expectation for data on viral testing and process evaluation for phase I studies and product licensing in the United States, Europe and Japan.
Moriguchi H
Dev Biol Stand; 1996; 88():143-7. PubMed ID: 9119127
[No Abstract] [Full Text] [Related]
60. Strategy for adventitious agent assays.
Robertson JS
Dev Biol Stand; 1996; 88():37-40. PubMed ID: 9119160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
